A model built on 20% average annual EPS growth over the next five years and a forward price-to-earnings ratio contracting to 20 points to Eli Lilly turning a $5,000 investment into roughly $10,100 by 2031. That would follow a five-year run in which the stock far outpaced the S&P 500, driven by its tirzepatide franchise, though new competition could slow the pace ahead.
The math behind the 2031 forecast
Assuming Eli Lilly's earnings per share grow at an average of 20% a year over the next five years while its forward price-to-earnings ratio contracts to 20, the company's market cap would grow from $1.09 trillion to $2.2 trillion, a roughly 15.1% annualized return. Under that scenario, a $5,000 stake today could be worth about $10,100 in five years.
That forecast follows a stretch in which Eli Lilly delivered a 35.86% compound annual growth rate, turning a $5,000 investment made five years ago into about $23,143. The S&P 500, by contrast, returned a 12.82% CAGR over the same period, growing $5,000 into $9,139.
Tirzepatide drove the past five years, but the pace won't repeat
Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management, was first approved in 2022 and is already the world's best-selling compound. It has driven Eli Lilly's sales and stock price higher, and the company's revenue and earnings have grown at rates well above average for pharmaceutical giants over the past five years. However, other companies will launch competing weight-loss medicines, which could pressure tirzepatide sales through lower volume and lower realized prices, and the drugmaker is unlikely to maintain its recent pace through 2031.
New drugs aim to keep the GLP-1 market expanding
Eli Lilly's Foundayo, an oral GLP-1 weight-loss medication that earned approval in April, saw 80% of its prescriptions go to patients who had never taken GLP-1s before, suggesting it is expanding the market rather than just cannibalizing Zepbound. Retatrutide, the company's next-gen obesity drug, has posted efficacy results some have compared to weight-loss surgery, and Eli Lilly is offering early access to certain patients with treatment-resistant obesity even though the drug hasn't received approval. Eloralintide, which mimics the amylin hormone, is also in development and could differentiate itself through better tolerability compared with GLP-1 medicines. Beyond obesity and diabetes, the company's pipeline extends into neuroscience, immunology, and oncology.
A premium valuation that assumes execution
Eli Lilly trades at 24.6 times forward earnings, compared with an average of 18.9 times for healthcare stocks. Clinical setbacks, slower-than-expected growth in the GLP-1 market, or more competition and price erosion than anticipated could all derail the projection.
Source: The Motley Fool
Trading involves risk.
Risk Disclaimer
